25.08.2020 • NewsBASFIdemitsu

BASF and Idemitsu End BDO JV

BASF, in mutual agreement with partner Idemitsu Kosan, has decided to end its joint-venture 1,4-butanediol (BDO) in Japan. Consequently, BASF Idemitsu’s BDO plant at Chiba, Japan, will close in December 2020. All 21 people employed at the plant will be offered alternative employment at either BASF or Idemitsu in Japan.

“The closure of the Chiba plant has become inevitable due to a declining BDO market size in Japan and significant overcapacities in Asia due to recent investments into new coal-based BDO production sites,” explained Masaru Saitoh, president of BASF Idemitsu.

China has become the world’s largest producer and consumer of BDO, adding much of the new capacity in recent years. However, the capacity increases has led to excess supply and lower prices for BDO.

BASF said its decision was part of an ongoing global review of long-term options for its options in the BDO value chain. The company added that it will continue to supply Japanese customers from its other BDO plants in Asia, North America and Europe.

 

Author: Elaine Burridge, Freelance Journalist

BASF, in mutual agreement with partner Idemitsu Kosan, is ending its...
BASF, in mutual agreement with partner Idemitsu Kosan, is ending its joint-venture 1,4-butanediol (BDO) in Japan because of the country’s declining market and significant overcapacity in Asia. Consequently, BASF Idemitsu’s BDO plant at Chiba, Japan, will close in December 2020. (c) BASF

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.